Caribou Biosciences Inc. (CRBU) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CRBU scores 33 out of 100, which corresponds to a letter grade of E and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 8 / 20. The source cites ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating a return on invested capital or free cash flow that would support valuation on cash-generation grounds.
• Whale 13F Flow: 3 / 20. This pillar reflects institutional accumulation and options positioning. The low score signals weak institutional support in the source data; no holder detail is provided to explain the drivers.
• Insider Conviction: 5 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider signaling of conviction in the source data.
• Macro Regime Fit: 6 / 20. The source cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is tracked at market-level volatility, but the score reflects weak alignment with the prevailing regime per the rating.
• Forensic Balance Sheet: 11 / 20. The source cites an Altman Z-Score of 2.5, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. These sit in a middle-to-weak band and point to balance-sheet fragility rather than strength.

Taken together, the rating frames CRBU as a high-risk situation where the primary upside case depends on events rather than current fundamentals. The price of $0.45 and the 52-week range of $0.41 to $3.54 show a steep decline, and the recent news wire reports a headline of a stock "plunges 40%" on a halt of CAR-T programs. A prospective investor should treat the rating as a warning that the stock's current valuation sits on uncertain future outcomes, not on demonstrated cash generation.

Caribou Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $0.0B on a rounded basis, while the market data section lists $47.7M. The source data does not describe specific products, customers, or revenue model beyond reported revenue figures in the financials. Revenue is reported at $11.2M for FY 2025, but the source does not attribute that revenue to particular products or counterparties.

Per the SEC financials, the company reported operating losses across all three periods, and net losses of $-148.1M in FY 2025 and $-149.1M in FY 2024. Revenue declined from $34.5M in FY 2023 to $10.0M in FY 2024 before rising to $11.2M in FY 2025. The market data section cites operating margin and net margin of -60% and gross margin of 0%. The rating cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 4/9, and the market data cites ROIC of -35%. Cash is reported at $12.4M for FY 2025 against FCF of $-112.4M, and debt is not available in source data for any period.

Per the recent news and catalysts section, the most prominent item is a headline reporting that the stock plunged 40% on the halt of CAR-T programs, flagged as a market wire item. A second item, flagged as a risk watch item, reports shares falling 35% after hours. Another headline reports the company will evaluate strategic alternatives, and a further item describes a "strategic alternatives" plan as a trigger for a herd-driven decline. One item carries a green catalyst flag, reporting a price target raised to $11 with implied upside of 869%. Per the butterfly supply-chain graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no sector correlations, and no proprietary signals recorded. The source data therefore does not identify specific supplier, customer, or sector linkages. An investor should note that the news flow references the halt of CAR-T programs, which is a pipeline-level event; the source does not map which partners, suppliers, or downstream programs are affected. Watch for any future disclosure that clarifies collaborative or manufacturing dependencies, since the current source is silent on these.

• What specific CAR-T programs were halted, and what is the disclosed financial impact on the company's pipeline and revenue base?
• What is the nature and timing of the strategic alternatives review, and what outcomes are under consideration?
• What is the company's debt position, since debt is listed as N/A across all reported periods?
• What is the cash runway implied by FY 2025 cash of $12.4M against FCF of $-112.4M?
• What drove the FY 2025 revenue recovery to $11.2M, and how durable is that revenue source?